Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
N.I.T. ENTERPRISE INC. INFOGRAPHICS of WEBSITE/PROJECTIONS/GOALS for 2015/16
http://www.nitenterprise.com/phone/index.html
BOOM BABY NIT ENTERPRISE ACTIVE SOS 100M A/S >>
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=NITENTERPRISESFL%20P140000424470&aggregateId=domp-p14000042447-c03bdd80-a6cf-4552-a288-a09e5aeca04b&searchTerm=NIT%20ENTERPRISE&listNameOrder=NITENTERPRISE%20P070000757810
PATENTED TECNOLOGY WITH FDA APPROVAL
NIT board ... Nice
Thanks for sharing those informative links! A must READ in the days to come.
NIT
NIT is in preliminary discussions with a Department of Defense agency regarding testing the technology for injection for military and first responder applications. Key reminder for the future rise in price on this one.
NIT
Great job on the IHub intro board!
Corporate Structure
NIT was incorporated in the State of Delaware in 2014 and is doing business in Florida. NIT was created to improve public safety and to provide a new measure of protection for commercial, industrial and personal products that enhance the longevity of living and non-living substances based upon unique proprietary NA technologies developed by our award winning scientist and technology team. This new technology is the infusion of ingredients, known as nucleotides, into a multiplicity of common products enhanced by their presence. The nucleotides were derived by atomic level research that
demonstrates their ability to provide Ultraviolet (UV) rays screening capability at the molecular level.
The Company is authorized to issue an aggregate of 105,000,000 shares of capital stock including 100,000,000 shares of common stock and 5,000,000 preferred stock. The Company is under common control with the management of Radiant Creations Group. NIT was formed to permit Radiant Creations Group (“Radiant”) to “spin-off” the NA technology. Upon the closing of the initial bridge financing, Radiant will transfer its NA technology to NIT in exchange for 100% of NIT’s common stock. This will permit Radiant to focus on its skin care product line. As part of the spin off, approximately 10,000,000 shares of common stock will be issued to the shareholders of Radiant as a dividend.
The Company is offering 5,000,000 shares of restricted common stock to accredited investors. Proceeds will be used to further develop NIT intellectual properties and provide for preparation of required SEC filing documentation.
Risks
As with all business venture, the development of new and innovative products has significant risks and uncertainties, even with advanced patented, patent-pending and proprietary technologies and methods, such as NIT. Some of these risks are discussed next, and Management believes these risks are some of the most significant concerns. Nevertheless, this list is not exhaustive and other issues need traditional discussion and reviews.
Technical Risks
There is a risk that NIT’s products could fail to meet regulatory requirements. Despite the advanced techniques and previous significant success of similar products, various complications could cause a selected product to fail certain regulatory requirements. If the selected product failed, additional monies would be needed to test other products. Such other products could also fail regulatory requirements.
Market Risks
There is a risk that NIT’s products, even after completing an initial scientific study, could be difficult to sell, or might not be purchased in volumes sufficient to achieve profitability. NIT’s proposed products have not been commercialized, and no prototypes built. Market risks for new industrial and military applications have increased over the past decade. Tight capital markets and reduced R&D budgets have forced companies to pursue lower risk and later stage licensing methods. Companies typically wait until the product has been shown to be marketable before pursuing an acquisition. Moreover, the proposed markets are difficult to penetrate and characterized by long sales cycles. On the upside, new OTC candidates at this stage can reach values far in excess of anticipated or protection results.
Financial Risks
NIT is a development-stage company and subject to all of the risks such companies face. Its financial statements required to be filed with the SEC will be qualified on a going concern basis. NIT has minimal working capital and is dependent upon raising most of the capital it is presently seeking as well as up to $500,000 it anticipates it will need over the 12 months following the offering.
Risk Summary
NIT faces technical and market risks. Risks of either kind could cause any investment in the company to be a material, and potentially complete loss.
Announcements and press releasesNIT Enterprises, Inc. Demonstrates Successful Radiation Shielding Test
Palm Beach Gardens, Florida – January 01, 2015 –
NIT Enterprises, Inc. (NITE) has completed successful testing of its patented lightweight ionizing X-Ray and Gamma Ray absorbing technology utilizing nano-strands of DNA and RNA with their associated nucleotides.
The ability to shield industrial materials without using heavy metals allows this technology to be applied in a myriad of applications where shielding is not possible for reasons of weight and size of currently existing methods. Application of NIT's shielding technologies provides a unique tool for new and existing product enhancements in healthcare, defense, space and industrial environments.
Nucleotides are approved by the FDA for injection into the human body. NIT is in preliminary discussions with a Department of Defense agency regarding testing the technology for injection for military and first responder applications. Governmental agencies have significant budget dollars set aside for applications which include radiation shielding for structures, vehicles, electronics and aerospace applications.
NIT's demonstration utilizes the unique bonding sites located on the sides of the DNA/RNA ladder where its patented process is used to bond heavy metal nano-particals creating a nano-sized wide spectrum radiation absorber. NIT has developed extensive positive data on its nucleotide micro-structures.
NIT's successful Gamma Ray tests were conducted at Borg Performance Coatings, LLC of Daytona Beach, Florida by their well-known chemist and chemical engineer, Mr. Bo Gimvang. The X-Ray tests were performed by Mr. Michael Latimer, M.S.R.S., RT(R) Clinical Coordinator Medical Imaging, an Assistant Professor at Palm Beach State College department of Radiography.
Gary Smith, CEO, of NIT stated "This discovery ranks as one of the most profound and valuable discoveries for almost limitless technological enhancement in industrial, medical and the chemical development. The potential revenues to be generated by commercialization of these exclusive technologies can be exploited through manufacturing and licensing production for disruptive applications which are also expected to generate significantly more intellectual property enhancements".
About NIT Enterprises, Inc. (NITE) (http://www.nitenterprise.com/)
NIT Enterprises, Inc. (d/b/a Nucleotide Industrial Technologies) (NITE) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products that enhance the longevity of living and non-living substances based upon unique proprietary NA technologies developed by our award winning scientist and technology team. This new technology is the infusion of ingredients, known as nucleotides, into a multiplicity of common products enhanced by their presence. The Nucleotides were derived by atomic level research that demonstrates their ability to provide Ultraviolet (UV) rays screening capability at the molecular level.
Cautionary Statement Concerning forward-Looking Statements:
This press release contains forward-looking statements that can be identified by words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects" and similar references to future periods.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Corporate Contact Information -
NIT Enterprise Inc. Harbour Financial Center, 2401 PGA Boulevard, Suite 280-N, Palm Beach Gardens, FL 33410; Phone: 561-508-6941
Investor Relations: Gary D. Alexander, Corporate Secretary; Email: NITEnterprises@yahoo.com
**rcgp** WEBSITES LOADED WITH INFO
http://www.radiantcreationsgroup.com/index.html
http://www.nitenterprise.com/index.html
http://www.nitenterprise.com/assets/nit_summary_v11.pdf
RCGP INCREASED REVS FROM 2013 TO 2014 +400%
$500,000 in 9 MONTHS
SHARE BUY BACK STARTING 2015
SHARE STRUCTURE
900,000,000 A/S
****60,000,000 FLOAT****
AS OF MARCH 24/2015
HUGE SPIN OFF SCHEDULED FOR MARCH 31, 2015
1 FOR EVERY 10 RCGP SHARES YOU HOLD
1,000,000 GETS YOU 100,000 NIT SHARES
COULD BE WORTH AS LITTLE AS $1.50 PPS AS PER CEO
>>>> MASSIVE REVENUE PROJECTIONS <<<<
RCGP & NIT
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
23
|
Created
|
03/25/15
|
Type
|
Free
|
Moderators |
"NIT is in preliminary discussions with a Department of Defense agency regarding testing the technology for injection for military and first responder applications. Government agencies have significant budget dollars set aside for applications which include radiation shielding for structures, vehicles, electronics, and aerospace applications."
As wavelengths grow shorter, their frequency increases in proportion, and rays and photons become more harmful to DNA, cell structure, and outdoor exposed surfaces. Although not having enough energy to ionize atoms,UV (Ultraviolet Radiation) does have the energy to alter chemical bonds, which is very damaging to DNA, paints, fabric, and plastics PRESIDENT OBAMA Appointed Li to the Medical Research Board >> Dr. Li has served on NIH grant boards and also was appointed to President Obama’s Stimulus Grant Board for medical research. He is considered one of the most productive geneticists in the world. Dr. Li had the honor of his work being featured on the March 2007 cover of Nature’s “Laboratory Investigations Journal” for discovering a prevention for alcohol related birth defects. Dr. Li has developed a non-invasive monitor that can detect Fetal Alcohol Syndrome in pregnant women. The monitor also presents the technical promise of non-invasive sugar level testing and real time monitoring of critical parameters during anesthesia. After fourteen years of research, Dr. Li found and patented a method to prevent DNA damage in the skin from UV and radiation. This work has been developed into Renewable’s DNA sun block. It is expected to be used to lessen the risk of skin cancer from sunlight and to act a protection of skin during radiation procedures. Dr. Li has residences in both the US and China. Dr. Li is an esteemed geneticist and invented a process to harvest stem cells from human urine and re-educate the cells to be stem cells used to grow other human organs. Dr. Li has developed a technique to multiply and store the cells for future use and is the developer of the products distributed by NIT Enterprises. His technologies and ingredients are patented; he is a world-renowned physician and geneticist with a stellar background and track record in basic medical science research including the fields of cellular, molecular and developmental biology, biochemistry and genomics, as well as clinic research experience in cardiology, gastroenterology and neonatology. Recipient of the Fogarty Fellowship, Dr. Li.’s prestigious career includes Duke, Vanderbilt, as well as the NIH.
ORIGINAL SCIENTIFIC CONTRIBUTIONS OF MAJOR SIGNIFICANCE IN THE FIELD
2. Developed an induced promoter DNA construct making antisense RNA targeted to wnt-1 oncogene, which significantly block the mammary tumor cell growth in mice. This work was praised by Nature Biotechnology in a review on gene therapy for cancer. (Nature Biotechnology April 1999, Volume 17, Number 4, Page 403-404.) In this international highly prestigious journal, Dr. Aris Persidis, the vice president for business development at Argonex Inc., wrote a review on antisense therapeutics research. In this review, the history and current state of antisense therapeutics programs to treat diseases ranging from cancer to AIDS were discussed. Dr. Persidis referred to Dr. Yin-Xiong Li’s work as a significant step toward the application of antisense treatment for virally induced cancer. The work referred to was published in Virology on March 1999, Volume 255, Page 138-149. 3. USA patent: Li Yin-Xiong, Nucleic Acid Filter For Tumorigenic Factors. USA Pending Number: 08939,858 USA, 2000. This patent describes a number of materials and methods to prevent the deleterious effects of DNA damaging agents, which are potent carcinogens. In particular, it presents a revolutionary breakthrough for sunscreen protection. This new sunscreen contains a component which filters out DNA damaging UV light much more efficiently than any previously described product. It also establishes an important new concept and standard for determining UV light induced DNA damage, the GPF (Gene Protection Factor). GPF more accurately reflects the protection efficiency of the sunscreen than does the classical SPF standard (Sunlight Protection Factor), which is determined by how well the sunscreen prevents the change in skin redness induced by UV light. 4. USA patent application: Li Yin-Xiong, Farrell, Michael and Margaret L. Kirby (1999). Double stranded blocks specific gene expression in muticellular settings in vivo and in vitro. This patent describes a novel method for attenuating the expression of targeted genes in tissue explants and in muticellular vertabrate embryos using double-stranded RNA. The ability to attenuate the expression of targeted genes in muticellular vertabrate tissues has broad implications for future medical applications. These may include anti-viral agents, anti-tumor agents, and other therapeutics that are designed to block the expression of specific genes or specific gene alleles, such as the autosomal dominant allele that causes Huntington’s chorea. 5. “Modern Experimental Technology of Molecular Biology”, 1993. Second Edition (1995). Third Edition (2000). National College Publishing Inc., Beijing, China. National Publishing Book Number: ISBN 7-04-004571-0/Q.215. This is a textbook for undergraduate and graduate students in Molecular Biology. Two editions of this book have been published. This is a textbook for undergraduate and graduate students in Molecular Biology. Two editions of this book have been published. This textbook has been used at more than 200 Universities in China including medical colleges, agricultural colleges, and in biology programs at universities. 6. Proposed new standard for cancer cell classification based on molecular oncogenesis pathology. This work was published in Journal of Experimental and Clinical Immunology, 2: 46-49, 1990. Two of the most popular media outlets in China have covered this story. The China Central TV station broadcast a story about this work at 9:00PM on November 15, 1989. The Peking People’s Radio Station broadcast a story about this work at 3:00PM on November 15, 1989. News programs at both stations reported that the work of Dr. Li Yin-Xiong and Dr. Shi-Dong Liao on a new molecular pathological classification of cancer cells, which made a significant step toward improving diagnosis and treatment of various tumors. 7. Successfully developed an RNA amplification approach to amplify RNA from Laser Capture. Microdissected few targeted cells and apply to oligonucleitids mrcroarray research. This provides a great potential to establish precise gene expression profile for any cell or tissue which involved interesting biological event or disease. 2001. 8. Invented a way to isolate and purify adult liver stem cells, and ten of these cells can rescue on damaged liver regeneration, 2005. 9. The molecular signaling defects result in stem cell developmental abnormalities, 2007. Discovered that alcohol-induced birth defects are rooted in small molecular alternation of cholesterol modification of a key protein, Shh. A breakthrough of molecular mechanism of alcohol-induced birth defects was published online in January 22, 2007 with a Press Release on Nature.com. In the first week after online publish, journalists from top five scientific magazines and over 100 websites reported the finding. These journals are: Science Daily, Nature.com, New Scientist (USA), Chemistry and Industry (England), Theheart.com (England), Daily Telegraph (London), Newsweek (Russia). This discovery has a profound impact on prevention and diagnosis of alcohol-induced birth defects and adult tissue damages. 10. Discovered cell signaling molecules, 2009. Three very important natural components have been found that function as nutrients for Adult Stem Cell; five components have been identified as signaling molecular among gastroenterological track and body tissues to regulate food intake and energy homeostasis. It holds a great potential for contorting obesity, hypotension, and diabetes. Dr. Li’s new concept “Stem Cell Nutrient” and related technology is monumental for leading adult stem cell based health care and clinical practice in the coming years. This technology will have a major impact in anti-aging, organ regeneration, and prevention of alcohol related disease
Most people are acquainted with UV-A and UV-B from sunblock advertisements. The general public has not been educated on the carcinogenic health, cell mutation, and cell death effects of high frequency UV-B, and industrially generated UV-C, which is present in all UV sterilization products. Cancer and cell death can be thousands of times more probable in these high frequency UV ranges. Studies have shown with current damage to the environment, a strong weather front can depress the protective ozone layer, even at mid-latitudes increasing the amount of high UV-B. Manufactured materials such as paint and fiberglass experience higher rates of degradation from UV-B. With the increased spectrum, this degradation is accelerated in today’s environment directly affecting all vehicles, aircraft, boats, exterior walls and roofs and any other structure exposed to sunlight.
As previously stated, man-made radiation levels, such as X-Rays and Gamma Rays, are higher than ever before. With NA used as a protective shield, the ionizing radiation can be absorbed and converted to infrared photons that are not harmful and are emitted into the atmosphere. This provides NIT with the capability to use the protective effects of NA in hospitals, clinics, dentist and doctor’s offices and industrial facilities; anywhere radiation is used as a tool.
Doctor’s offices and medical facilities have a host of radiation emitting equipment. The American Medical Association reports there are over 815,000 US licensed physicians, and the American Dental Association lists more than 157,000 dentist members. These members’ offices, as well as thousands of hospitals, both federal and commercial are potential customers for NA incorporated in paints or building materials in offices and medical facilities. Hospitals alone have three times the background Ionizing Radiation of normal work environments.
Manufactured materials such as paint and fiberglass all fade from impact from UV radiation. This degradation is accelerated in today’s environment directly affecting all vehicles, aircraft, boats, exterior walls and roofs and any other structure exposed to sunlight.
Dr. Li accomplished impressive results in laboratory comparison of automotive paint UV resistance technology compared to the same paint with NIT’s NA, obtaining several times the paint life over existing UV protection technology. The work was performed by Dr. Li’s colleagues at Duke University’s Pratt School of Engineering. Potentially using NA to extend UV performance of such high performance paints extends to the marine, aircraft and industrial coatings markets. An excellent potential market is to sell NA additive to large multi-national paint resin manufacturers. NIT staff has a very close relationship with Bayer Material Sciences, one of the largest worldwide high technology resin raw material suppliers. NIT staff has briefed Bayer top executives and business development groups on the NA as a new product upgrade for their resins. NIT intends to offer Bayer a license after joint testing in selected resin products. Sales directly to paint manufacturers who make their own resins is also a prime potential market for NA. NIT has close ties to vehicle and aircraft paint manufacturers through its association with tint manufacturer and distributor BeadBrite Research LLC. BeadBrite has existing business with virtually every Tier 1 automotive paint manufacturer. BeadBrite is also closely associated with the paint specification groups for original equipment manufacturer vehicle manufacturers. A potential companion market to paint for trans-parent surfaces is the window and window film market. These products suffer both degradation from normal UV and have no current protections against high frequency UV. Plastic windows can be impregnated with NA, and glass can be coated with an NA coating. After market coatings and window films can employ NA. | ||||||
NEWS:
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |